Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2021 | Liso-cel for R/R large B-cell lymphoma

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the recent FDA approval of lisocabtagene maraleucel (liso-cel) for relapsed or refractory (R/R) large B-cell lymphoma. Prof. Jäger considers this approval another milestone in the lymphoma field that now has three CAR-T products available. The approval of liso-cel in Europe is expected soon. This interview took place during the 3rd European CAR T-cell Meeting.

Transcript (edited for clarity)

The approval of liso-cel is another big step forward because now we have three products. Liso-cel has shown excellent efficacy in several different lymphoma entities, transformed follicular lymphomas, but also in the classical indications, diffuse large B-cell lymphoma after second-line.

I think with this new product, which is different from the other two in a way that the ratio between T4 and T8 is balanced, will give us new opportunities...

The approval of liso-cel is another big step forward because now we have three products. Liso-cel has shown excellent efficacy in several different lymphoma entities, transformed follicular lymphomas, but also in the classical indications, diffuse large B-cell lymphoma after second-line.

I think with this new product, which is different from the other two in a way that the ratio between T4 and T8 is balanced, will give us new opportunities. We’ve had the chance to use the product in clinical studies. I think we will also see approval in Europe pretty soon. Of course, that will help us to broaden the possibilities for our patients. One particular aspect, maybe, with the liso-cel, of course, is that in the studies, there were also some patients with CNS involvement included, which will also broaden our armamentarium in terms of applying this product to this kind of patients, where other products have, at least, not been studied in detail.

Read more...

Disclosures

Grant, personal fees, and nonfinancial support from Novartis, Bristol Myers Squibb/Celgene, Gilead, Janssen, Merck, and Roche
Grant and personal fees from Sanofi
Personal fees and nonfinancial support from AbbVie, Amgen, AOP Orphan, Miltenyi Biotec, Sandoz, and Takeda